Abingworth Life Science - Public Market Investing

Abingworth aims to invest in undervalued public companies that have the potential to provide venture capital-like returns. The company uses its networks, financial expertise and industry knowledge to select firms with experienced management and products or technology with significant commercial potential.

Abingworth invests in public companies through its venture funds and through Abingworth BioEquities (ABE), a separate open-ended fund that invests only in quoted life science companies. ABE’s strategy is to invest globally in under-appreciated public life science companies that have the potential to deliver high returns over a two to four year investment period.

As of October 2010, Abingworth had public market funds under management of over $450 million. This figure includes more than $180 million in VIPEs, $120 million in companies that were previously venture investments and over $145 million in open market positions.

John Maraganore, President and CEO of Alnylam Pharmaceuticals

A critical step in building Alnylam (Nasdaq: ALNY) was its merger with Ribopharma, an Abingworth portfolio company. Abingworth had the vision of linking our two efforts together to build a stronger company. Since the merger, we have benefited greatly from support and guidance from the broader Abingworth team. Their input has been invaluable in making progress on our scientific R&D and business objectives.